Blood Cancer

AbbVie's Decnupaz Secures FDA Approval for Rare Blood Cancer

The US FDA has approved AbbVie's antibody-drug conjugate, Decnupaz (pivekimab sunirine-pvzy), for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This marks AbbVie's first ADC entry in the blood cancer space and the first ADC approval for this ultra-rare indication.

Bristol Myers Unveils Next-Gen Blood Cancer Drug Data

Bristol Myers has revealed promising data for its next-generation blood cancer drug, Mezigdomide. This article explores the implications for the pharmaceutical landscape.

AbbVie Secures FDA Approval for ImmunoGen's Elahere in Rare Blood Cancer

AbbVie has received FDA approval for Elahere, a significant advancement in the treatment of rare blood cancers. This article explores the implications for pharmaceutical teams and investors.

Orca Bio's Orca-Q Receives FDA RMAT Designation for High-Risk Blood Cancers Treatment

Orca Bio's Orca-Q therapy gains FDA RMAT designation for high-risk hematologic malignancies based on promising Phase 1 survival and safety data.